Braeden Lichti: Investing in Anti-Aging and Rejuvenation Biotechnology
By: Theravest Management
VANCOUVER, British Columbia - Oct. 18, 2019 - PRLog -- Scientists today now have a better understanding into the aging process, giving us a better explanation of the cellular changes that lead our body and brain to decline as we age. Many believe that inflammation, stress, diet, exercise, and genetics greatly contribute to our aging process.
New studies are pointing to promising treatments that could slow, stop, or even reverse the signs of aging. This isn't just about turning back the clock in order to have a longer life span, its about extending our healthy years.
In one study, mice were given pills that mimicked the positive benefits of exercise. If it works in mice would it be effective in humans? And what does this portend for the future, if our lifespan increases and we all live decades longer?
The business of anti-aging and rejuvenation is gaining steam and should be on the radar of investors — the Bank of America has forecasted that the market will balloon from $110 billion today, to nearly to $610 billion by 2025.
Researchers have jumped on this trend too. In 2012, only 73 trials were conducted to reverse aging and that number doubled by the end of 2017 to 145. In 2018, this industry accounted for the most significant amount of investment, as market participants attracted an amount close to $800M (for comparison, back in 2014, it was only about $100M). The number of investment deals is also growing, with the highest number of the past six years recorded in 2017 (25 according to CB Insights, up from 13 a year earlier).
Companies like Juvenescence have raised over $65M to build an ecosystem and pipeline of assets targeting aging, age-related disease and regeneration. Juvenescence believes that recent scientific and medical advances will enable the development of therapeutics that meaningfully improve human health and extends our lifespan.
Here are additional industry developments we're excited about:
Juvenescence's portfolio currently includes Insilico Medicine, a next-generation artificial intelligence company specializing in the application of deep learning to drug discovery and ageing research. Juvenescence AI, a joint venture with Insilico Medicine focused on the clinical development of AI-generated compounds.
LyGenesis, a company with technology to use a patient's own lymph nodes as bioreactors to grow functioning ectopic organs.
AgeX Therapeutics, a company applying intellectual property related to cell immortality and pluripotency.
Finding the latest developments
We encourage investors to follow the latest advancements in anti-ageing and rejuvenation by reading magazines such as Nature and The New Scientist. Both publications recently featured interesting articles that highlighted recent developments. We also recommend following websites like fiercebiotech, scientificamerican and tracking Initial Public Offerings to find other companies developing innovative anti-aging technologies.
Whether you are looking for an early-stage investment opportunity or would like to join an investment at a later stage, be sure to do your homework or team up with a group that works together to buy or build biotech opportunities.
Contact us today: https://theravestmanagement.com/
DISCLAIMER: All insights, suggestions, and advice provided herein are for educational purposes only. Nothing contained in this article or within this web site should be interpreted as a recommendation to buy or sell any securities, nor make an offer, solicitation or recommendation of another kind. All readers should always do further research before making a final investment decision.
The author is not a United States Securities Dealer nor Broker nor US Investment Adviser.